Dr. Ritu Gupta leads the Unit of Laboratory Oncology at the All-India Institute of Medical Sciences (AIIMS). A clinician-scientist and hematopathologist, she is engaged in translational research and has contributed to the development of ethnicity-specific, AI-enabled risk stratification models for patients with multiple myeloma, thereby refining cancer staging and prognostication across resource-diverse healthcare settings.
Dr. Gupta established India’s first fully robotic clinical laboratory at the National Cancer Institute (NCI), in addition to founding a Unit of Excellence for Multiple Myeloma Research and a Centre for Advanced Research in Acute Myeloid Leukemia at AIIMS. She has also played an important role in drafting national guidelines in laboratory diagnostics.
As a Fulbright-Nehru scholar, Dr. Gupta is expanding her research on next-generation strategies for monitoring therapeutic responses in the evolving era of cellular cancer therapeutics. Her current work is directed toward the creation of patient-centric diagnostic workflows that intelligently integrate therapeutic modality, clinically actionable turnaround times, and infrastructure considerations to facilitate timely and individualized intervention.
In addition, Dr. Gupta is engaging with students, scholars, and investigators, sharing her perspective on the integration of clinical, patient-specific, and tumor-biological variables with artificial intelligence to develop robust, evidence-based, and future-ready paradigms in cancer diagnostics.